Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00466232 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer
A Phase 1 study, sponsored by HealthPartners Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT00466232 is a Phase 1 study that has completed, run by HealthPartners Institute. The registered enrollment target is 16 participants.
The verdict
NCT00466232, a Phase 1 study, has completed, sponsored by HealthPartners Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the maximum tolerated dose of sorafenib up to the full active dose when combined with standard weekly dosing of topotecan in patients with recurrent small cell lung cancer and to characterize the toxicities associated with the combination of topotecan and sorafenib in this patient population
Interventions
- DRUG Topotecan
- DRUG Sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2007-04 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00466232
The ClinicalTrials.gov registry entry for NCT00466232 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HealthPartners Institute, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Topotecan is the first listed.
NCT00466232 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00466232 about?
NCT00466232 is a clinical study titled "Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer". The primary objective of this study is to determine the maximum tolerated dose of sorafenib up to the full active dose when combined with standard weekly dosing of topotecan in patients with recurrent small cell lung cancer and to characterize the toxicities associated with the combination of topote...
What is the current status of trial NCT00466232?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2007-04. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00466232?
The interventions under investigation include: Topotecan (DRUG), Sorafenib (DRUG).
Who is sponsoring clinical trial NCT00466232?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.